In its Q1 2026 filing, Protara Therapeutics reported steady advancement in its investigational cell therapy program TARA-002 targeting non-muscle invasive bladder cancer and lymphatic malformations, alongside maintenance of robust liquidity supporting at least twelve months of operations. The company remains early-stage, with no approved products or revenues, focusing on clinical development funded by capital raises. Growth hinges on successful trial outcomes and regulatory milestones, while risks include high development risk and dependence on third-party manufacturing. The cash position of approximately $14.7 million and strong current ratio underpin operational continuity but emphasize the need for additional financing to sustain the pipeline.